We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep our audiences informed about upcoming FDA approvals. This newsletter analyzes drugs and biologics in development. Our Q3 2021 edition offers insight on high-cost drug and biologic approvals, such as:
- New treatments on the horizon for epidermolysis bullosa.
- The latest on messenger ribonucleic acid (mRNA) technology.
- Potential Food and Drug Administration-approved bevacizumab formulations for wet age-related macular degeneration.
- The possible first FDA-approved therapeutic aryl hydrocarbon receptor modulating agent (TAMA) for plaque psoriasis.